Skip to content
Research/Peptides/ARA-290 (Cibinetide)

ARA-290 (Cibinetide)

ARA-290, a non-erythropoietic peptide, represents a significant advancement in neuroprotective therapies, particularly for small fiber neuropathy. Engineered to activate the innate repair receptor (IRR) pathway, it offers tissue protection without stimulating red blood cells. Phase II clinical trials have shown efficacy in improving metabolic control and neuropathic symptoms among diabetic patients and individuals with sarcoidosis. With a promising safety profile and ongoing research into various therapeutic applications, ARA-290 is poised to make a considerable impact in neuropathy treatment.

Intelligence Profile

Research Papers

Research Papers and Clinical Trials

ARA-290 (also known as Cibinetide) is an erythropoietin-derived peptide that has been studied across multiple therapeutic areas. The compound works through the β-common receptor pathway rather than traditional erythropoietin receptors, allowing it to provide tissue-protective effects without stimulating red blood cell production.

Neurological Applications

Several studies have investigated ARA-290's neuroprotective properties. A 2024 study published in CNS Neuroscience & Therapeutics demonstrated that ARA290 provides brain tissue protection in mice with cerebral ischemic stroke by acting through the β-common receptor. Additional research from 2025 in Frontiers in Neurology explored the potential of phase-targeted erythropoietin derivatives, including ARA-290, for traumatic brain injury treatment. A separate 2024 review in International Immunopharmacology examined the protective effects of erythropoietin-derived peptides in peripheral nerve injury.

Cardiovascular and Metabolic Effects

Research published in Frontiers in Cardiovascular Medicine (2022) found that this small erythropoietin-derived peptide reduced cardiac inflammation, helped maintain heart function with aging, and extended healthspan in animal models. The anti-inflammatory properties appear to be a key mechanism across multiple therapeutic applications.

Other Applications

Studies have explored ARA-290's effects in kidney disease, bone health, and autoimmune conditions. A 2023 study in Inflammation investigated the compound's protective effects against cisplatin-induced kidney toxicity, focusing on apoptosis and inflammatory pathways. Research published in the International Journal of Molecular Sciences (2021) showed that Cibinetide inhibited bone-destroying cell activity and increased bone mineral density in mice.

Clinical Trials

Four clinical trials have been registered for ARA-290, though results and current status vary:

  • A Phase 2 trial examined effects in prediabetes and type 2 diabetes (NCT01933529), with unknown current status
  • A Phase 2 study for diabetic macular edema was terminated (NCT06626971)
  • A completed Phase 2 trial (NCT02039687) studied the compound's effects on corneal nerve fiber density and neuropathic symptoms in sarcoidosis patients
  • A completed Phase 1/2 study (NCT02070783) investigated cognitive and neural effects

The research suggests ARA-290 has broad anti-inflammatory and tissue-protective properties across multiple organ systems, though clinical development appears to have faced challenges based on the terminated trials. The completed studies' results are not detailed in the available evidence.

This information is for educational purposes only and should not be considered medical advice. Consult healthcare professionals for medical guidance.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.